The Opportunity
- Insulin:glucagon platform will become a replacement for rapid acting insulin that can be used anywhere and with any patient type (T1D, T2D, Injections, pumps)
- Insulin:glucagon platform protects against hypoglycemia allowing safer use of insulin and better control of diabetes that in turn allows much improved long term health
- Pharmacological platform leverages two well known peptides (many decades of use in humans)
- Proof of concept already achieved with prototype co-formulations
- De-risked and streamlined path to market
- Non-dilutive funding, strong IP position
Milestones
- Proof of concept in a large animal model
- Human POC study using a co-infusion has validated the approach
- Candidate formulations demonstrate feasibility of a stable combination product
- Strong IP Portfolio
- Non-dilutive funding to date